270
Participants
Start Date
August 4, 2025
Primary Completion Date
August 1, 2028
Study Completion Date
August 31, 2032
Dabrafenib + Trametinib
There is no different use in the clinical application of the drugs reported above, the study on fertility will be implemented in the women with completely resected melanoma enrolled in the study
Pembrolizumab
There is no different use in the clinical application of the drugs reported above, the study on fertility will be implemented in the women with completely resected melanoma enrolled in the study
Nivolumab
There is no different use in the clinical application of the drugs reported above, the study on fertility will be implemented in the women with completely resected melanoma enrolled in the study
Observation
Patients who will not initiate adjuvant therapy, but will undergo observation (due to refusal, comorbidities, other reasons).
NOT_YET_RECRUITING
Università di Torino - Clinica Dermatologica, Torino
NOT_YET_RECRUITING
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
NOT_YET_RECRUITING
IOV Istituto Oncologico Veneto, Padua
NOT_YET_RECRUITING
Azienda Ospedaliero-Universitaria, Modena, Modena
NOT_YET_RECRUITING
Università degli Studi di Siena - U.O.C. Immunoterapia Oncologica Azienda Ospedaliera Universitaria Senese, Siena
NOT_YET_RECRUITING
"Ospedale Oncologico Giovanni Paolo II", Bari
NOT_YET_RECRUITING
"Istituto Nazionale Tumori Fondazione Pascale", Napoli
NOT_YET_RECRUITING
IRCCS Ospedale Policlinico San Martino, Oncologia Medica 2, Genova
RECRUITING
Azienda Ospedaliera Santa Maria della Misericordia - Unità di Oncologia Medica., Perugia
NOT_YET_RECRUITING
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
Intergruppo Melanoma Italiano
OTHER